A nurse is reinforcing teaching about the iPLEDGE program with a female client who has a new prescription for isotretinoin.
The nurse should tell the client that which of the following is a requirement of the program?
A.
Female clients must have a negative mammogram prior to beginning therapy.
B.
Clients must have a Papanicolaou test every 6 months during treatment.
C.
Clients must begin a daily supplement of vitamin A for 1 month prior to initiating therapy.
D.
Sexually active female clients must use two forms of birth control during treatment.
The Correct Answer and Explanation is :
The correct answer is D. Sexually active female clients must use two forms of birth control during treatment.
Explanation:
The iPLEDGE program is a risk management program mandated by the U.S. Food and Drug Administration (FDA) for patients taking isotretinoin, a powerful medication used to treat severe acne. Isotretinoin is highly effective but also carries significant risks, particularly for female patients of childbearing age, due to its potential to cause severe birth defects. Therefore, the iPLEDGE program has stringent requirements to prevent pregnancy during treatment.
Requirement of Two Forms of Birth Control:
One of the key requirements of the iPLEDGE program is that sexually active female patients must use two forms of birth control simultaneously while taking isotretinoin. This is crucial because isotretinoin is known to cause severe fetal abnormalities, and the risk of birth defects is heightened if pregnancy occurs during treatment. The use of two forms of contraception—one primary method such as hormonal birth control (e.g., pills, patches, or injections) and one secondary method (e.g., barrier methods such as condoms)—significantly reduces the risk of unintended pregnancy.
Additional Aspects of iPLEDGE:
- Negative Pregnancy Test: Female patients must have a negative pregnancy test before starting isotretinoin therapy and must undergo regular pregnancy tests during the treatment. This ensures that the patient is not pregnant when beginning the medication and helps to monitor for any potential pregnancy during the course of treatment.
- Education and Consent: Patients are required to sign a consent form acknowledging the risks associated with isotretinoin and their understanding of the need for effective contraception.
- Enrollment in iPLEDGE: Both the patient and the prescriber must be enrolled in the iPLEDGE program, and prescriptions can only be filled by authorized pharmacies.
The other options mentioned do not align with the iPLEDGE program requirements. Mammograms (A) and Papanicolaou tests (B) are not part of the iPLEDGE requirements for isotretinoin use, and there is no mandate for patients to take vitamin A supplements (C) prior to starting therapy, as isotretinoin is a derivative of vitamin A and excess intake can be harmful.
In summary, the iPLEDGE program emphasizes the necessity of using two forms of birth control to mitigate the risk of pregnancy and protect the health of potential future pregnancies while on isotretinoin.